Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 105
- Registration Number
- NCT06781983
- Locations
- 🇫🇷
Gustave Roussy Cancer Institute, Villejuif, France
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸Mount Sinai Tisch Cancer Center, New York, New York, United States
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 184
- Registration Number
- NCT06088654
- Locations
- 🇺🇸
Icahn School Of Medicine At Mount Sinai, New York, New York, United States
🇫🇷Hôpital de la Coception, Marseille, France
🇺🇸City of Hope, Duarte, California, United States
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Drug: IPH5201 + durvalumab + standard chemotherapy
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 70
- Registration Number
- NCT05742607
- Locations
- 🇬🇷
University General Hospital of Patras, Patras, Greece
🇫🇷Charles Nicolle Hospital, Rouen, France
ðŸ‡ðŸ‡ºPulmonology Institute Torokbalint, Torokbalint, Hungary
Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- Biological: lacutamab
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT05321147
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇺🇸University of Alabama at Birmingham- O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
- Conditions
- Lymphoma, T-Cell, CutaneousLymphoma, T-CellMycosis Fungoides/Sezary Syndrome
- Interventions
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 170
- Registration Number
- NCT03902184
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California, United States
🇺🇸Inova Health Care Services, Fairfax, Virginia, United States
IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: IPH5401 and Durvalumab
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 73
- Registration Number
- NCT03665129
- Locations
- 🇺🇸
ICAHN School of Medicine at Mount Sinai, New York, New York, United States
🇫🇷Centre Hospitalier Universitaire- Hôpital Nord Laennec, Nantes, France
🇺🇸Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Head and Neck Neoplasms
- Interventions
- Biological: MonalizumabBiological: CetuximabBiological: Anti-PD(L)1
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 143
- Registration Number
- NCT02643550
- Locations
- 🇺🇸
University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
- Conditions
- Cutaneous T-Cell Lymphoma
- Interventions
- Biological: IPH4102
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 44
- Registration Number
- NCT02593045
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸Stanford Cancer Center, Stanford, California, United States
🇳🇱Leiden University Medical Center, Leiden, Netherlands
Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 22
- Registration Number
- NCT02557516
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity
- Conditions
- Squamous Cell Carcinoma of the Oral Cavity
- Interventions
- First Posted Date
- 2015-01-06
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 3
- Registration Number
- NCT02331875
- Locations
- 🇪🇸
Instituto Catalan de Oncologia - L'Hospitalet, L'Hospitalet de Llobregat Barcelona, Spain
🇪🇸Hospital Universitario La Paz, Madrid, Spain
🇩🇪Charité University Medicine Berlin, Berlin, Germany